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Abstract This review covers publications on siderophores
applied for molecular imaging applications, mainly for
radionuclide-based imaging. Siderophores are low molec-
ular weight chelators produced by bacteria and fungi to
scavenge essential iron. Research on these molecules has a
continuing history over the past 50 years. Many biomedical
applications have been developed, most prominently the
use of the siderophore desferrioxamine (DFO) to tackle
iron overload related diseases. Recent research described
the upregulation of siderophore production and transport
systems during infection. Replacing iron in siderophores by
radionuclides, the most prominent Ga-68 for PET, opens
approaches for targeted imaging of infection; the proof of
principle has been reported for fungal infections using
68Ga-triacetylfusarinine C (TAFC). Additionally, fluores-
cent siderophores and therapeutic conjugates have been
described and may be translated to optical imaging and
theranostic applications. Siderophores have also been
applied as bifunctional chelators, initially DFO as chelator
for Ga-67 and more recently for Zr-89 where it has become
the standard chelator in Immuno-PET. Improved DFO
constructs and bifunctional chelators based on cyclic
siderophores have recently been developed for Ga-68 and
Zr-89 and show promising properties for radiopharma-
ceutical development in PET. A huge potential from basic
biomedical research on siderophores still awaits to be uti-
lized for clinical and translational imaging.
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Introduction
Progress in Molecular Imaging applications in particular in
the context of radionuclide-based technologies is dependent
on highly specific tracers aiming at an increasing number of
available molecular targets. The development of radiophar-
maceuticals is impressively advancing based on the progress
in radiopharmaceutical chemistry embracing the increasing
understanding of the molecular basis of pathophysiology in
many clinical fields. Radiometals have been an essential part
in this development, initially driven by technetium-99m
based radiopharmaceutical developments, today overtaken
by the interest in positron emission tomography (PET) with
the implementation of gallium-68 in clinical routine and
other radiometals entering the arena including zirconium-89,
copper-64, scandium-44 and others. Integration of
radiometals in ‘‘biomolecules’’ requires the attachment of a
chelator binding the metal with high stability without
impairing affinity to the target. Nature has designed specific
chelators for a variety ofmetals; an important group is the so-
called siderophores (from Greek translating to ‘‘Iron-Car-
rier’’) for binding ferric ions, produced by bacteria, fungi and
plants. This review summarizes applications of siderophores
as chelators for general molecular imaging applications and
in particular in the field of infection imaging.
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Methods
Siderophores have been very widely investigated in
biomedical research. A systematic search in PubMed was
carried out, taking into account publications until August
2016. The search term ‘‘Siderophore’’ reveals 11,205 hits
in PubMed (August 2016), starting from 1953 with first
publications on Mycobactin [1]. Figure 1a shows the dis-
tribution of publication over the last 60 years indicating the
constant interest of the scientific community in side-
rophores in biomedical research including preclinical and
clinical applications. Combining the search term ‘‘Side-
rophore(s)’’ or the most widely used siderophore ‘‘Des-
ferrioxamine’’ with key words related to imaging such as
‘‘Imaging’’, ‘‘Radionuclide’’, ‘‘PET’’, ‘‘scintigraphy’’ or
specific radionuclides all together 699 publications were
found with relations of siderophores to imaging applica-
tions (Fig. 1b). Even though systematic search was carried
out, the high number of publications made a selection of
recent, up to date reviews on the general topic of side-
rophores or on 89Zr labelling based on siderophores nec-
essary. This review also did not intend to analyse the
clinical applications or outcomes; meta-analysis or risk
assessment was, therefore, not applied.
Microbial siderophores
Iron is an essential cofactor for a variety of cellular pro-
cesses in all eukaryotes and most prokaryotes including
respiration, amino acid metabolism, and biosynthesis of
DNA and sterols. Despite its high abundance in the Earth’s
crust, the bioavailability of iron is extremely low owing to
its oxidation by atmospheric oxygen into sparely soluble
ferric hydroxides with a solubility of 10-18 M at pH 7.0.
Moreover, for pathogens in both plant and animal hosts,
iron is usually not freely available but tightly sequestered,
e.g. in vertebrates associated with proteins such as trans-
ferrin, ferritin and haemoglobin. Blocking iron access to
invading microbes represents a key pathway in host
defence as a component of innate immunity, termed ‘‘nu-
tritional immunity’’ [2, 3]. Consequently, pathogenic as
well as non-pathogenic organisms had to evolve sophisti-
cated strategies to ensure iron supply. Microorganisms are
believed to lack mechanisms for iron excretion and,
therefore, control of iron uptake is considered the major
iron homeostatic mechanism. To satisfy the iron need in
diverse niches, bacteria and fungi use different iron
acquisition mechanisms, which are transcriptionally
upregulated during iron limitation: (1) direct ferrous iron
(Fe2?) uptake, (2) direct ferric iron (Fe3?) uptake, (3)
siderophore-mediated ferric iron uptake, and (4) uptake and
degradation of haeme. Most microbial species employ
more than one system in parallel but not all species use all
four strategies. With few exceptions, bacterial and fungal
species secrete siderophores to scavenge extracellular iron.
Siderophores, low molecular mass (B1 kD), ferric iron-
specific chelators, display a remarkable species-specific,
structural diversity with[500 different siderophores being
identified [4, 5]. Some bacteria possess plasma membrane-
localized siderophores, e.g. mycobactins of mycobacteria.
In contrast to bacteria, most fungi also possess intracellular
siderophores for intracellular transport and storage of iron.
Siderophores contain the most efficient iron-binding ligand
types in nature, consisting of hydroxamate, catecholate or
a-hydroxy-carboxylate ligands (Fig. 2). The most efficient
siderophores form hexadentate complexes, satisfying the
six co-ordination sites on ferric ions allowing iron-binding
constants of 1020–1050. Examples are enterobactin in the
catecholate class, triacetylfusarinine C (TAFC), ferriox-
amines (FOX) E and G, as well as the ferrichromes in the
Fig. 1 Interest in siderophores in Biomedical Research over the last
60 years based on PubMed-listed publications; a search term using
‘‘Siderophore’’ presented in hits/decade; b publication hits combining
search terms ‘‘Siderophore’’ with various Imaging key words
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hydroxamate class and staphyloferrin in the a-hydroxy-
carboxylate class (Fig. 2) [6]. The majority of e.g. fungal
siderophores belong to the hydroxamate class. Fungal
hydroxamate siderophores can be grouped into four struc-
tural families: fusarinines, coprogens, ferrichromes and
rhodotorulic acid [6]. The hydroxamate group is built by
acylation of the non-proteinogenic amino acid N5-hydroxy-
L-ornithine, which is derived by hydroxylation of L-or-
nithine, with acetyl or more complex groups such as
anhydromevalonyl. Most fungal siderophores include three
of these moieties linked by ester or peptide bonds to form
the most efficient hexadentate structures. Cyclization of the
siderophore is found in ferrichromes and some fusarinines.
Although linear hexadentate siderophores are found in all
siderophore classes, there is a tendency for cyclization,
thereby enhancing complex and chemical stability.
Siderophore metabolism is highly specific to microbes:
Siderophore production involves enzymes that are found
exclusively in bacteria and fungi, e.g. nonribosomal pep-
tide synthetases, and siderophore uptake is mediated by
specific transporters. In bacteria and fungi, siderophore
uptake is mediated by different transport systems. For
example, in gram-negative bacteria siderophores have to
cross both the outer membrane and the plasma membrane;
e.g. ferrichrome type siderophores are transported through
the outer membrane via the receptor FhuA, which is
energized by the plasma membrane-localized TonB com-
plex, and transported across the plasma membrane via
ABC-transporter-dependent movement [7]. In contrast,
cellular uptake of siderophore-iron complexes in fungi is
mediated by ‘‘siderophore-iron transporters’’ (SITs), which
belong to a subfamily of the major facilitator protein
superfamily [8]. SITs act most likely as proton symporters
energized by the plasma membrane potential. SIT-medi-
ated iron uptake is universally conserved in the fungal
kingdom, even in species not producing siderophores such
as Saccharomyces cerevisiae, Candida spp. and Crypto-
coccus neoformans [9]. Moreover, most bacterial and
fungal species are able to utilize not only the endogenous
siderophores but also siderophore types that are produced
by other bacterial or fungal species (so-called
xenosiderophores).
Taken together, both siderophore biosynthesis and their
specific cellular uptake are confined to the bacterial and
fungal kingdoms. Moreover, there is overwhelming evi-
dence that the siderophore system is active during infec-
tion; e.g. (1) siderophore biosynthesis and uptake are
transcriptionally upregulated during iron starvation in vitro
as well as in vivo in a murine model for pulmonary
infection with the mold Aspergillus fumigatus (A. f.)
Fig. 2 Basic ferric-coordination units (top) and examples of natural siderophores (bottom)
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[10, 11], and (2) genetic inactivation of siderophore
biosynthesis attenuates virulence of A. f. in a murine
infection model, which demonstrates that siderophore-
mediated iron assimilation plays the major role for viru-
lence [12, 13]. Moreover, the siderophore of A. f., tri-
acetylfusarinine C (TAFC) was shown to be able to extract
iron from host transferrin [14]. A scheme of TAFC-medi-
ated iron uptake is shown in Fig. 3. Similarly, siderophore
biosynthesis was shown to be crucial for the virulence of
numerous bacterial species including, e.g. Yersinia pestis,
Mycobacterium tuberculosis or Pseudomonas aeruginosa
[e.g. 15]. As a result, siderophores were suggested as
biomarkers in aspergillosis and tuberculosis [16, 17]. Due
to the function of siderophores as virulence determinants,
mammals evolved siderophore sequestering proteins, ter-
med siderocalins, and pathogens evolved mechanisms to
avoid recognition of their siderophores by siderocalins
[18].
Unequivocally, siderophores play a profound role in iron
acquisition of most microorganisms. Nevertheless, there
are evidences that siderophores can chelate also other
metals with physiological relevance, e.g. the siderophore
yersiniabactin was recently found to sequester extracellular
copper to protect uropathogenic Escherichia coli from
copper toxicity during human infection [19], while some
siderophores appear to be involved in uptake of various
non-iron metals such as yersiniabactin in zinc uptake by
Yersina pestis [20, 21]. Due to the indispensability of
siderophore-mediated iron acquisition, this system is
hijacked during microbial competition, e.g. the outer
membrane ferrichrome-type siderophore receptor of E. coli
serves also as receptor for various bacteriophages [22] and
naturally evolved siderophore-antibiotic conjugates, ter-
med sideromycins, in which a bactericidal warhead is
attached to a siderophore moiety [20, 21]. For instance,
albomycins comprise a hydroxamate siderophore unit,
reminiscent of those found in fungal ferrichromes, and
bactericidal unit that inhibits seryl-tRNA synthetase.
Albomycins display a broad-spectrum of antibiotic activity
again both Gram-negative and Gram-positive bacteria
because of the widespread nature of ferrichrome receptors.
These natural ‘‘Trojan horses’’ inspired the development of
designed synthetic conjugates [23]. Similarly, gallium salts
have been described as potential anti-infectives. In this
case, gallium is bound to siderophores and taken up by the
pathogen via the siderophore transport system which neg-
atively interferes as iron analogue with the pathogens’s
iron homeostasis [24]. A human application of side-
rophores, which is not related to infectious diseases, is the
use of desferrioxamine, a siderophore produced by Strep-
tomycetes spp, in treatment of iron overload such as tha-
lassemia to mobilize and decrease body iron stores [25].
Siderophores for molecular imaging of infection
The accurate localization and characterization of infection
and its distinction from inflammation have emerged as one
of the greatest challenges of modern medicine. Identifica-
tion of patients at high risk and early and accurate diag-
nosis remains crucial for their successful therapy and
underlines the urgent need for specific and sensitive diag-
nostic tools. Molecular imaging methods hold the potential
to provide a more robust, non-invasive, selective and
Fig. 3 Siderophore-mediated iron uptake in the mold A. fumigatus.
a The cyclic trihydroxamate siderophores FSC (R = H) and TAFC
(R = acetyl) are shown in the ferri-form; for TAFC-based nuclear
imaging, the iron (shaded in red) is replaced by 68Ga. b TAFC-
mediated uptake of iron and gallium into fungal hyphae. TAFC is
secreted by an unidentified exporter and the iron/gallium-siderophore
complex is taken up by the siderophore transporter MirB. Within the
cell, iron release from the siderophore is facilitated by TAFC
hydrolysis by the esterase EstB [5]
18 Clin Transl Imaging (2017) 5:15–27
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sensitive diagnosis of infections leading to improved clin-
ical decisions and a fundamental change in patient man-
agement with better healthcare outcomes [26].
Radiological imaging techniques such as computed
tomography (CT), magnetic resonance imaging (MRI) and
ultrasonography (US) are widely used in clinical practice
for identification of infection, although they have major
limitations in specificity [27]. Optical imaging represents
an interesting future approach to molecular imaging of
infection, but no optical probes have been licensed for
routine use in the clinic for microbial detection [28]. By
contrast, nuclear imaging techniques including PET and
SPECT have a rich history of different radiolabelled probes
(radiopharmaceuticals) for imaging of infectious processes
in patients. These include 111In- or 99mTc-labelled leuco-
cytes, 99mTc-anti-granulocyte antibody, 99mTc-diphospho-
nates in the context of bone scanning, 67Ga-citrate and
2-[18F]-fluorodeoxyglucose [26]. These probes target pre-
dominantly secondary effects of infection such as increased
blood flow and vascular permeability, activated endothelial
cells or polymorphonuclear cell migration limiting their
specificity or have other shortcomings related to blood
manipulation or induction of immune response (HAMA)
[29, 30]. Even though new developments are emerging
especially for bacterial infections such as radiolabelled
antimicrobial peptides [26], nuclear medicine clinicians are
still awaiting improved radiopharmaceuticals overcoming
these limitations.
An interesting group of molecules, which could fulfill
the requirements on the ‘optimal imaging agent’ for
molecular imaging of infections, appears to be (radio)la-
belled siderophores. Table 1 summarizes applications of
siderophores as imaging agents. They can be prepared
either by the introduction of appropriate radiometal to the
natural (iron-)siderophore complex via the exchange of
iron or artificially by the modification of natural side-
rophore with a chromophore suitable for optical imaging
[31–34]. Already in the 1970s and 1980s, first investiga-
tions of radiolabelled siderophores, including desferriox-
amine (DFO), were already reported with gamma-emitting
radionuclides—67Ga and 111In [35–38]. Gallium is an
isosteric diamagnetic substitute for Fe(III) [39] and, thus,
the affinity constants of many siderophores for gallium are
in the range of their iron counterparts. At that time, it was
also demonstrated that under reducing conditions, Ga(III)
can rapidly displace Fe(III) from siderophores, whereas
without concerted reduction of the iron no significant
exchange was observed [40]. Emery and Hoffer [41] have
used 67Ga to study the uptake mechanisms for different
siderophores in Ustilago sphaerogena and found this
energy-dependent process to be indistinguishable from that
of its Fe(III) counterpart. They even postulated an
involvement of siderophore binding in the accumulation of
67Ga-citrate in inflammatory lesions. A number of inves-
tigations were made with 3H, 14C, 55Fe and 59Fe labelled
siderophores mainly to study iron transport or siderophore
uptake mechanisms in microorganisms or plants [e.g.
42–44] unsuitable for molecular imaging and, therefore,
cannot be used for detection of microbial infections
in vivo. By contrast, radionuclides used in the studies of
Table 1 Applications of siderophores as imaging agents
Imaging
modality
Type of label Siderophore Application Reference





SPECT 67Ga, 111In Enterobactin Ligand for
radiopharmaceuticals
[37]




Microbial iron transport [40, 51]
PET 68Ga, 89Zr Ferrichrome, ferrichrome A,
triacetylfusarinine C,
desferrioxamine, desferrioxamine
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Moerlein and Emery [37, 40, 41]—67Ga and 111In—have
found widespread use in nuclear medicine for SPECT
imaging. Over the past decade, PET has experienced a
significant increase applying a variety of positron emitting
radiometals [45]. Recently, 68Ga use in particular is
showing a dramatic growth because of the applicability in
labelling of diverse range of compounds and because it is
obtained from a long shelf-life and relatively inexpensive
68Ge/68Ga generator system [46].
More than 30 years after the first attempts of labelling
siderophores with 67Ga [36–38, 40, 41], we evaluated the
use of 68Ga labelled siderophores for PET imaging of
fungal infections [47]. In proof of concept studies, which
should confirm or refute the possibility of PET imaging of
infections caused by Aspergillus fumigatus (A. f.) using
68Ga-siderophores [48], it was demonstrated that desfer-
risiderophores, particularly triacetylfusarinine C (TAFC),
can be easily radiolabelled with 68Ga using a few micro-
grams of the siderophore and exhibit high chemical sta-
bility. Uptake of 68Ga-TAFC by A. f. was upregulated
under iron starvation conditions and could be blocked with
an excess of siderophore or NaN3, indicating specific and
energy-dependent uptake. A variety of different side-
rophores such as fusarinine C (FSC), TAFC, coprogen,
various ferrichrome and ferrioxamine-type-siderophores
displayed excellent 68Ga-radiolabeling properties [49].
However, only 68Ga-TAFC and 68Ga-ferrioxamine E
(FOXE), a siderophore produced by Streptomycetes, dis-
played a good combination of fungal uptake in culture,
suitable pharmacokinetics for imaging (i.e. rapid clearance
from organs and circulation with predominant renal
excretion) and, in particular, excellent metabolic stability
[50]. Significantly different in vivo behaviour compared to
68Ga-citrate (i.e. non-specific infection and inflammation
PET imaging agent) was also found [51]. High contrast
imaging of A. f. pulmonary infection in a rat model was
achieved using micro-PET/CT technology [50, 52],
exhibiting pronounced accumulation of 68Ga-TAFC in
infected areas extremely early after onset of infection,
which increased with severity of infection and correlated
with abnormal CT images (Fig. 4). Significant accumula-
tion of 68Ga TAFC was found neither in sterile inflam-
mations nor in tumour cells [53], which also have a high
iron metabolism. We also investigated the uptake of 68Ga-
TAFC in a number of different fungal and bacterial spe-
cies, which revealed high specificity for Aspergillus spe-
cies, with no significant uptake by Candida and bacterial
species, in particular. By comparison, FOXE displayed
high in vitro uptake by Staphylococcus aureus, which was
surprisingly not confirmed in vivo [53]. An interesting
exception among Aspergillus species is Aspergillus terreus,
which lacks the ability to take up TAFC but accumulates
FOXE. Besides the investigations with siderophores
labelled with 68Ga, we have also attempted to radiolabel
siderophores with different radionuclides. So far we have
succeeded to label TAFC, FOXE, desferrichrome A
(FCHA) and DFO with zirconium-89 [54]. The interest in
89Zr has increased over the last years as it displays almost
ideal properties allowing imaging of biological processes at
late time points after the tracer application. Even though
Fig. 4 Micro-PET/CT (Albira PET/SPECT/CT small animal imaging
system, Bruker Biospin Corporation, Woodbridge, CT, USA) imaging
of A. fumigatus [coronal slices (a) and 3D images (b)] in a rat
infection model and non-infected rat (c) 45 min post-intravenous
injection of 68Ga-TAFC showing clear accumulation in infected
[(a) and (b)] and no accumulation in healthy c lung tissue
20 Clin Transl Imaging (2017) 5:15–27
123
89Zr has comparably low positron abundance and due to the
long half-life (78.4 h) results in higher radiation dose, it
allows long-term follow-up especially of slowly accumu-
lating biomolecules such as antibodies, nanoparticles and
other large biomolecules both for preclinical and clinical
applications, thereby complementing 68Ga with its limita-
tions of a very short half-life (67.7 min). Comparing the
in vitro and in vivo characteristics of 68Ga-siderophores
with their 89Zr counterparts, we found analogous properties
with the potential for longitudinal Aspergillus infection
imaging [54]. From all these studies, we concluded that
68Ga-labelled siderophores, in particular 68Ga-TAFC, have
a high potential to be used as radiopharmaceuticals to
specifically image Aspergillus infections in patients.
Overall radiolabelled Siderophores certainly have the
potential to be a highly specific tool for infection imag-
ing, considering the essential role of the siderophore
system for iron acquisition and virulence of microorgan-
isms together with its upregulation during infection,
whereas they are not utilized by mammals. This is also
related to the low toxicity of siderophores exemplified by
DFO, which is used safely in close to gram amounts for
iron overload disease repeatedly. Selecting appropriate
siderophores can also lead to a high specificity for par-
ticular microorganisms, e.g. being able to distinguish
between certain fungal and bacterial infections. The
requirement for upregulation of the siderophore trans-
porters to accumulate the radiolabelled siderophore,
however, will require a rather acute status of infection;
therefore, it can be expected that its main role can be
envisaged in a rather acute setting, such as detection and
specific characterization of invasive Aspergillosis, with its
live-threatening consequences rather than in a more
chronic or less aggressive infection setting. This can only
be revealed in a clinical setting; therefore, the first clinical
studies of 68Ga-siderophores are currently eagerly
awaited.
Besides radiolabelling, also other attempts have been
made to use siderophores for pathogen detection. Several
groups have developed strategies of synthesizing side-
rophore-chromophore conjugates for optical imaging
[31–33, 55–58]. Siderophores (e.g. ferrichromes, pyochelin
and DFO) derivatized with various fluorescent probes, such
as fluorescein, rhodamine, 7-nitrobenz-2-oxa-1,3-diazole
and anthracene, were used for the monitoring of side-
rophore transport in different microorganisms including
bacteria (e.g. Pseudomonas spp.) [31, 32, 58] and fungi
(Ustilago maydis, Saccharomyces cerevisiae, Candida
albicans and Rhizzopus arrhizus) [33, 55, 57]. The
microbial activity was not altered by the attachment of
various functionalities and fluorescent siderophore ana-
logues became invaluable tools in the investigation of
molecular mechanisms involved in microbial iron transport
and acquisition. Accordingly, these artificial siderophore
analogues could also serve as a tool for in vivo diagnostic
imaging or targeting of microbial pathogens [34].
The recognition of the role of siderophores as important
microbial iron transporters has led to the exploitation of
this pathway in a ‘Trojan Horse’ strategy not only for
pathogen detection, but also for the development of ther-
apeutic strategies [34, 59]. Banin et al. [60] have used
siderophore-metal complex combining a strong side-
rophore, DFO with non-radioactive gallium for the treat-
ment of Pseudomonas aeruginosa (P.a.) infection. The Ga-
DFO complex was designed as an antioxidant that acts by
‘push and pull’ mechanism, sequestering ferric ions (the
siderophore effect) and, in turn, releasing gallium ions that
further compete with ferric ions at iron-binding sites of
proteins. The Ga-DFO served as a ‘Trojan Horse’ that
interferes with iron metabolism and delivers toxic gallium
to P.a. cells. The antimicrobial effect of Ga-DFO to P.a.
infections showed promising results; nevertheless, it war-
rants further investigation. Moreover, a number of studies
on complex siderophore-drug conjugates have been made
to test their potential as effective antimicrobial agents
[23, 34, 61–63]. It could be speculated that these side-
rophore conjugates could be radiolabelled or derivatized
and used for molecular imaging of infections.
Siderophores as bifunctional chelators
Table 2 summarizes applications of siderophores as
bifunctional chelators, combining the two functions of
metal coordination with the coupling property to a target-
ing vector.
Desferrioxamine and gallium
Already early in the development of targeted radiophar-
maceuticals, siderophores were considered as chelators for
radiometals. Initial studies focussed on gallium-67 as a
gamma-emitting isotope with a half-life of 78.3 h for pla-
nar scintigraphy and SPECT imaging. 67Ga-Citrate was
introduced for tumour studies and due to its similarities
with Fe3? DFO was proposed to enhance tumour to blood
ratios in tumour imaging [64]. Three hydroxamate groups
of DFO coordinate Ga3? with fast kinetics and high
affinity, forming a stable 1:1 chelate with high radio-
chemical yield. The free amino group can be used as
coupling side to bioactive molecules. Already in 1982, the
proof of principle was shown by coupling DFO to albumin
for binding 67Ga, proposing DFO as bifunctional chelating
agent [65]. A glutaraldehyde coupling reaction was applied
and the authors showed a superior in vivo stability of 67Ga-
DFO-HSA over 131I-labelled HSA and provided first
Clin Transl Imaging (2017) 5:15–27 21
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images in patients. A first targeted application was reported
in the same year by coupling DFO to fibrinogen [66]. A
large number of DFO molecules were introduced to human
fibrinogen using dialdehyde starch (DAS) as a spacer-
functional polymer. Increased accumulation of 67Ga-fib-
rinogen in venous thrombi was depicted at 48 h after
injection about 60 % of patients [67]. Other applications of
DFO-conjugated macromolecules followed soon with
radiolabelled lectins [68], which failed in tumour detection.
A more successful approach was the development of DFO-
conjugated monoclonal antibodies and antibody fragments.
Motta-Hennessy C et al. [69] established conditions for the
coupling of DFO with the bifunctional reagent glutaralde-
hyde to two rat IgG2b monoclonal antibodies M10/76 and
11/160, specific for the Hooded rat sarcomata MC 24 and
HSN, respectively, which maintained their capacity for
binding to their tumour-associated antigens. Koizumi et al.
[70] compared the homocoupling reagent glutaraldehyde
with two other heterocoupling reagents, N-succinimidyl-3-
(2-pyridyldi-thio)propionate and succinimidyl-6-maleimi-
dohexanoate, linking desferrioxamine to antibodies through
alkylamine, disulphide, and thioether bonds, and showed
superiority of thioether bonds in terms of tumour targeting
and pharmacokinetics. Bartal et al. [71] compared the
labelling of MAb 23H7, binding to human sarcoma, with
67Ga using glutaraldehyde-coupled DFO and 111In via
DTPA, whereby higher specific activities were achieved
with 67Ga. Amino-dextran-DFO was used to derivatise an
anti-melanoma monoclonal antibody (TP41) for labelling
with In-111 with promising results especially reduced liver
uptake [72]. DFO as bifunctional chelator for antibodies was
also proposed for radiotherapeutic applications using 67Ga
Auger electrons. Govindan et al. [73] prepared different
DFO-antibody conjugates and reported two main problems
limiting further development. First, the stability was inade-
quate for the 3-day half-life of the nuclide. Second, the labels
were poorly retainedwithin cells after Ab internalization and
catabolism. More recently, a novel bifunctional chelate
(BFC) p-isothiocyanatobenzyl-DFO (Df-Bz-NCS), origi-
nally developed for 89Zr labelling, was used to prepare anti-
EGF Nanobody conjugates of DFO for 68Ga labelling for
PET applications [74]. Fast radiolabelling, high tumour
uptake and tumour to normal tissue ratios in nude mice
bearing A431 xenografts were obtained with the fast kinetics
of the 68Ga-Nanobody conjugates, indicating a promising
application of DFO conjugates with 68Ga.
Besides proteins also smaller molecules were conju-
gated to DFO for radiolabelling with 67/68Ga. Folic acid
was covalently linked to DFO via an amide bond using a
simple carbodiimide coupling reaction. 67Ga-DF-fo-
late(gamma) exhibited specific uptake and was proposed as
a diagnostic agent for noninvasive imaging of folate
receptor-positing tumours [75]. 67/68Ga-DFO-Octreotide
(SDZ 216-927), comprising DFO coupled to octreotide via
a succinyl linker [76, 77], showed specific uptake in
Somatostatin receptor expressing tumour models and was
proposed as PET imaging agent. However, in patients 67Ga
DFO-Octreotide radioactivity was detectable in the circu-
lation even after 24 h; the blood clearance curve was much
slower than the one of OctreoScan (111In-DTPA-Oc-
treotide) due to relatively high protein binding in human
serum [78]. So, overall a number of attempts have been
made to develop siderophore-bioconjugates based on DFO
for radiolabelling with 67/68Ga and to a limited extent with
111In, however, with inconclusive results in particular
related to its stability especially at high specific activities
[79], thereby being replaced mainly by aminocarboxylate-
based chelators such as DOTA or NOTA.
Table 2 Applications of
siderophores as bifunctional
chelators
Radionuclide Siderophore Radiopharmaceutical References
67Ga DFO Albumin [65]
67Ga DFO Fibrinogen [66, 67]
67Ga, 111In DFO Antibodies [69–73]
68Ga DFO Nanobodies [74]
67Ga DFO Folate [75]
67/68Ga DFO Octreotide [76–78]
89Zr DFO Antibodies [82–84]
89Zr DFO RGD peptides [91]
89Zr DFO Nanoparticles, carbon nanotubes,
microspheres
[92–94]
89Zr DFO Nanocolloids [95]
89Zr DFO Proteins [96, 97]
89Zr DFO* Bombesins [100]
68Ga FSC Peptide multimers [101, 102, 104]
89Zr FSC Peptide multimers [103]
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Desferrioxamine and zirconium-89
In contrast to that in the past decade, DFO has established
its role in the context of 89Zr-labelling [80–84]. 89Zr was
proposed as a diagnostic radionuclide for quantitating the
biodistribution of radiolabelled antibodies. The high
affinity of zirconium for hydroxamic acid groups makes
DFO a suitable and effective chelator for Zr4?. Meijs and
co-workers initially reported that DFO exhibits rapid and
efficient labelling with a 1:1 ratio of metal to chelate and
demonstrates good stability with regard to demetallation,
releasing less than 0.2 % of the metal in serum after 24 h
[85]. Further evaluation of the complex by Holland and co-
workers utilizing density functional theory (DFT) models
exhibited Zr-DFO as an octadentate complex combining
the six binding oxygens of DFO with two additional water
molecules. Also, stability studies over longer periods of
time indicated that still less than 2 % demetallation occurs
after 7 days in serum [86].
The first clinical trial with an 89Zr-labelled antibody
revealed the low immunogenicity of the DFO-conjugate
[87] allowing repeated applications of the DFO immuno-
conjugate. For the coupling of DFO to antibodies, most
widely 2,3,5,6 tetrafluorophenyl TFP-activated ester of N-
succinyl-DFO-Fe forming stable amide bonds with free
amines have been applied [88], or alternatively p-isothio-
cyanato-DFO forming a stable thiourea bond with lysine
residues [89]. Standardized protocols have been established
[90] making 89Zr labelling for Immuno-PET applications
ever more widely applicable. Several reviews have sum-
marized the latest progress of 89Zr-DFO-conjugated anti-
bodies [82–84].
The use of 89Zr-labelled bioactive molecules using
siderophores is not limited to the antibodies. Beyond
antibodies, 89Zr-DFO conjugated to peptides and peptide
multimers [91], nanoparticles [92, 93], carbon nanotubes
[94], Albumin nanocolloids [95], and proteins [96, 97] has
also been investigated.
Improvement of DFO for 89Zr
Despite the prevalent use of 89Zr-DFO-conjugated anti-
bodies for preclinical studies and clinical applications,
several preclinical studies reported bone accumulation of
dissociated 89Zr ranging from 3 to 15 % after 3–7 days
[86, 98, 99]. This insufficient stability of the 89Zr-DFO
complexes is attributed to the incomplete coordination of
89Zr4? by DFO and the linear structure of DFO. Based on
the knowledge of DFO, Patra et al. developed an
octadentate DFO analogue termed DFO*, which fully sat-
urates the coordination sphere of Zr4?, by coupling an
additional hydroxamic acid entity to DFO [100]. DFT
calculations predicted the expected molecular structure
involving coordination through the eight oxygen atoms of
all four hydroxamic acid moieties. Coupling the model
peptide bombesin ([Nle14]BBS(7–14)), DFO*-bombesin
showed a remarkably improved stability in comparison to
the DFO analogue when challenged with 300- to 3000-fold
molar excess DFO over the course of 1 day. The in vitro
experiment demonstrated that the new chelator did not
influence the properties of the peptidic vector. Based on
those results, DFO* holds promise to provide new PET
imaging agents with superior stability profiles; applications
on DFO* coupled antibodies are awaited soon.
Other siderophores as bifunctional chelators
Recently, we reported that Fusarinine C (FSC), a repre-
sentative of the class of hydroxamate siderophores, is a
promising 68Ga and 89Zr bifunctional chelator [101–104].
FSC, possessing three hydroxamic acid groups for binding
68Ga or 89Zr similar to DFO embedding an additional
cyclic structure, offers a potential advantage with respect to
the stability of 68Ga/89Zr complexes. FSC not only allows
fast and highly selective labelling with 68Ga in a wide pH
range and results in high specific activities, but also shows
very high stability of 68Ga-FSC complexes at low con-
centration demonstrating the superiority over DFO which
was reported to be unstable at low ligand concentrations
(\50 nM) [79]. Compared to 89Zr-DFO, 89Zr-FSC deriva-
tives showed excellent in vitro stability and resistance
against transchelation in phosphate-buffered saline (PBS),
ethylenediaminetetraacetic acid solution (EDTA) and
human serum for up to 7 days making it an alternative as
89Zr BFC [103]. The three primary amines of FSC facilitate
the derivatization of FSC with targeting biomolecules in a
number of ways, also applying the concept of multiva-
lency. By attaching a cyclic RGD peptide, binding to
integrin avb3 expressed during angiogenesis, via a succinic
acid linker (FSC-(RGD)3), high stability
68Ga complexes
with excellent receptor-binding properties and in vivo tar-
geting were prepared (Fig. 5), superior to monomeric [68-
Ga]NODAGA-RGD [104]. Currently, monovalency- and
divalency FSC for 68Ga/89Zr labelling are under investi-
gation and different coupling strategies e.g. click chemistry
are being investigated.
Conclusion
Extensive publications from the last decades have descri-
bed a wide variety of Fe3? binding siderophores produced
by bacteria and fungi. Their role in iron acquisition and
human diseases has been reported and methods for chem-
ical modification, chemical synthesis and even radiola-
belling with a variety of radiometals are available. This
Clin Transl Imaging (2017) 5:15–27 23
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knowledge has been translated towards radiopharmaceuti-
cals for molecular imaging in general and specific imaging
of infection in particular. There are many opportunities to
further use this knowledge towards development of new,
improved radiopharmaceuticals for molecular imaging in
PET, but also towards theranostics and optical imaging
applications.
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